Po-amitriptyline 10mg: Ndma Impurity
APO-AMITRIPTYLINE 10mg tablets are being recalled across Canada because they contain NDMA, a chemical impurity that poses a safety risk. This recall affects all patients taking this medication. The recall is classified as Class I, meaning the impurity could cause serious health problems.
- Product
- APO-AMITRIPTYLINE 10mg
- Reason
- Product safety
- Classification
- Class I
- Category
- drug recall
- Country
- Canada
- Agency
- HC-DRUGS
- Recall date
- 2022-01-26
- Status
- Ongoing
- Distribution
- Canada-wide
Official recall notice from HC-DRUGS
Recall details on Nibble Recalls: https://trynibble.app/recalls/ce5d4eb7-097f-4baf-b267-80659198feb2